Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6597)
All Articles published online
|
Publishing Process of This Article
|
Dec 15, 2013 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Moradi A, Sepah YJ, Sadiq MA, Nasir H, Kherani S, Sophie R, Do DV, Nguyen QD. Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. World J Diabetes 2013; 4(6): 303-309 [PMID: 24379921 DOI: 10.4239/wjd.v4.i6.303] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v4/i6/303.htm |
| Number | Citing Articles |
| 1 |
Deep Shikha Sharma, Sheetu Wadhwa, Monica Gulati, Arya Kadukkattil Ramanunny, Ankit Awasthi, Sachin Kumar Singh, Rubiya Khursheed, Leander Corrie, Nitin Chitranshi, Vivek Kumar Gupta, Sukriti Vishwas. Recent advances in intraocular and novel drug delivery systems for the treatment of diabetic retinopathy. Expert Opinion on Drug Delivery 2021; 18(5): 553 doi: 10.1080/17425247.2021.1846518
|
| 2 |
E Al Kahtani, Z Xu, S Al Rashaed, L Wu, A Mahale, J Tian, E B Abboud, N G Ghazi, I Kozak, V Gupta, J F Arevalo, E J Duh. Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment. Eye 2017; 31(4): 529 doi: 10.1038/eye.2016.246
|
| 3 |
Shigeo Yoshida, Tomoaki Murakami, Miho Nozaki, Kiyoshi Suzuma, Takayuki Baba, Takao Hirano, Osamu Sawada, Masahiko Sugimoto, Yoshihiro Takamura, Eiko Tsuiki. Review of clinical studies and recommendation for a therapeutic flow chart for diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology 2021; 259(4): 815 doi: 10.1007/s00417-020-04936-w
|
| 4 |
Hanife Rahmanlar, Cemile Üçgül Atılgan, Mehmet Çıtırık, İbrahim Muaz Yaradılmış, Hakkı Gürsöz. Türkiye’de Diyabetik Retinopati Tanısında Endikasyon Dışı İlaç Kullanımı. Sakarya Medical Journal 2019; 9(3): 499 doi: 10.31832/smj.543998
|
| 5 |
Irini Chatziralli, Anat Loewenstein. Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature. Pharmaceutics 2021; 13(8): 1137 doi: 10.3390/pharmaceutics13081137
|
| 6 |
Blessing C. Ilochonwu, Arto Urtti, Wim E. Hennink, Tina Vermonden. Intravitreal hydrogels for sustained release of therapeutic proteins. Journal of Controlled Release 2020; 326: 419 doi: 10.1016/j.jconrel.2020.07.031
|
| 7 |
Fatma Savur, Havva Kaldırım, Kürşat Atalay, Tülin Öğreden, Şerife Çiloğlu Hayat. Treatment results of diabetic macular edema with different choroidal thickness with intravitreal anti vascular endothelial growth factor. BMC Ophthalmology 2022; 22(1) doi: 10.1186/s12886-022-02721-3
|
| 8 |
Joana F. Fangueiro, Amélia M. Silva, Maria L. Garcia, Eliana B. Souto. Current nanotechnology approaches for the treatment and management of diabetic retinopathy. European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 307 doi: 10.1016/j.ejpb.2014.12.023
|
| 9 |
Haiyan Chen, Xuehui Shi, Wang Zhang, Qianqian Han. Aflibercept versus ranibizumab for diabetic macular edema: A meta-analysis. European Journal of Ophthalmology 2024; 34(3): 615 doi: 10.1177/11206721231178658
|
| 10 |
Işıl Kutlutürk Karagöz, Adil Allahverdiyev, Melehat Bağırova, Emrah Şefik Abamor, Sahar Dinparvar. Current Approaches in Treatment of Diabetic Retinopathy and Future Perspectives. Journal of Ocular Pharmacology and Therapeutics 2020; 36(7): 487 doi: 10.1089/jop.2019.0137
|
| 11 |
Farheen Tariq, Yanfen Wang, Bo Ma, Yidan He, Shu Zhang, Ling Bai. Efficacy of Intravitreal Injection of Filtered Modified Low-Dose Triamcinolone Acetonide and Ranibizumab on Pseudophakic Cystoid Macular Edema. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.777549
|
| 12 |
Douglas A. MacDonald, Joel Martin, Kathir K. Muthusamy, Jiann-Kae Luo, Erica Pyles, Ashique Rafique, Tammy Huang, Terra Potocky, Yang Liu, Jingtai Cao, Françoise Bono, Nathalie Delesque, Pierre Savi, John Francis, Ali Amirkhosravi, Todd Meyer, Carmelo Romano, Meredith Glinka, George D. Yancopoulos, Neil Stahl, Stanley J. Wiegand, Nicholas Papadopoulos. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes. Angiogenesis 2016; 19(3): 389 doi: 10.1007/s10456-016-9515-8
|
| 13 |
Walid S. Ibrahim, Zeiad H. Eldaly, Mohamed G. Saleh, Mahmoud F. Rateb, Ahmed H. Aldoghaimy. Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs. Korean Journal of Ophthalmology 2019; 33(2): 122 doi: 10.3341/kjo.2018.0037
|
| 14 |
Imène Zhioua, Oudy Semoun, Franck Lalloum, Eric H. Souied. INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMA. Retina 2015; 35(7): 1429 doi: 10.1097/IAE.0000000000000490
|
| 15 |
Lyndell L Lim, Julie L Morrison, Marios Constantinou, Sophie Rogers, Sukhpal S Sandhu, Sanjeewa S Wickremasinghe, Ryo Kawasaki, Salmaan Al‐Qureshi. Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery – preliminary 6 month results. Clinical & Experimental Ophthalmology 2016; 44(4): 233 doi: 10.1111/ceo.12720
|
| 16 |
Eda I. Altiok, Shane Browne, Emily Khuc, Elizabeth P. Moran, Fangfang Qiu, Kelu Zhou, Jorge L. Santiago-Ortiz, Jian-xing Ma, Matilda F. Chan, Kevin E. Healy, Guei-Sheung Liu. sFlt Multivalent Conjugates Inhibit Angiogenesis and Improve Half-Life In Vivo. PLOS ONE 2016; 11(6): e0155990 doi: 10.1371/journal.pone.0155990
|
| 17 |
Havva Kaldırım, Serpil Yazgan, Ahmet Kırgız, Kursat Atalay, Fatma Savur. A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment. Current Eye Research 2019; 44(9): 987 doi: 10.1080/02713683.2019.1608260
|
| 18 |
Dante Akira Kondo Kuroiwa, Fernando Korn Malerbi, Caio Vinicius Saito Regatieri. New Insights in Resistant Diabetic Macular Edema. Ophthalmologica 2021; 244(6): 485 doi: 10.1159/000516614
|
| 19 |
Kuan Hao Yee, Srinivasan Sanjay. Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Effective?. EMJ Diabetes 2017; : 118 doi: 10.33590/emjdiabet/10313316
|
| 20 |
Jean-Francois Korobelnik, Jos Kleijnen, Shona H Lang, Richard Birnie, Regina M Leadley, Kate Misso, Gill Worthy, Dominic Muston, Diana V Do. Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME). BMC Ophthalmology 2015; 15(1) doi: 10.1186/s12886-015-0035-x
|
| 21 |
Giannis-Aimant Moustafa, Marilita M Moschos. Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa - a first case report and short review of the literature. BMC Ophthalmology 2015; 15(1) doi: 10.1186/s12886-015-0033-z
|
| 22 |
Sanket U. Shah, Raj K. Maturi. Therapeutic Options in Refractory Diabetic Macular Oedema. Drugs 2017; 77(5): 481 doi: 10.1007/s40265-017-0704-6
|